<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/abio-20230224.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Form 8-K - Current report - Item 2.02 Item 9.01

ARCA biopharma Inc

Announcement: ABIO 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/0000950170-23-004379-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

ARCA Biopharma reviews strategic options for maximizing shareholder value
Current Analysis:
ARCA Biopharma is a precision medicine biopharmaceutical company that applies gene-specific targeting to develop targeted therapies for cardiovascular diseases. The company’s Gencaro product is a pharmacogenetically-targeted beta-adrenergic receptor that lowers vasodilator properties and is designed to treat atrial fibrillation (AF) in patients with heart failure. Currently, there are limited treatment options in the market that can effectively address AF or heart failure. ARCA Biopharma is conducting a strategic review process to explore options such as mergers, sale of assets, or other alternatives that may enhance stockholder value.

Forward-Looking Analysis:
The AF market has significant potential and is expected to grow by $5.5 billion by 2025. With the observed positive clinical trial results for Gencaro treating atrial fibrillation (AF), ARCA Biopharma is in a favorable position to leverage the growth opportunities in this market. Although phase 3 clinical trial for Gencaro is yet to be completed, criteria such as “preventing AF and avoiding drug-related complications” as secondary endpoints suggests positive results for treatment. If clinically approved, Gencaro could offer a welcome alternative that is both safe and effective for higher ejection fraction HF patients with AF.

Announcement: ABIO 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023002622/abio-20230210.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017023002622/0000950170-23-002622-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 5.02 Item 9.01

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000156761923002070/doc1.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/907654/000156761923002070/0001567619-23-002070-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ABIO SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/abio-20221215.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 5.02 Item 5.07 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-20221208.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/907654/000095017022026298/0000950170-22-026298-index.htm>Original filing index</a>
                        </div>